TELA Bio, Inc. (NASDAQ:TELA - Get Free Report) insider Gregory A. Firestone bought 6,666 shares of TELA Bio stock in a transaction that occurred on Thursday, October 24th. The shares were acquired at an average cost of $2.25 per share, with a total value of $14,998.50. Following the acquisition, the insider now owns 57,279 shares of the company's stock, valued at $128,877.75. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
TELA Bio Price Performance
Shares of TELA stock opened at $2.58 on Friday. The company has a debt-to-equity ratio of 14.22, a current ratio of 3.41 and a quick ratio of 2.52. The firm's 50-day moving average is $2.68 and its two-hundred day moving average is $4.16. TELA Bio, Inc. has a 12 month low of $2.30 and a 12 month high of $7.84. The company has a market capitalization of $63.75 million, a PE ratio of -1.50 and a beta of 0.99.
TELA Bio (NASDAQ:TELA - Get Free Report) last issued its earnings results on Monday, August 12th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.06). TELA Bio had a negative return on equity of 252.57% and a negative net margin of 65.04%. The firm had revenue of $16.09 million for the quarter, compared to analysts' expectations of $19.00 million. During the same period last year, the firm earned ($0.46) earnings per share. Analysts predict that TELA Bio, Inc. will post -1.39 earnings per share for the current year.
Hedge Funds Weigh In On TELA Bio
Blackrock’s Sending THIS Crypto Higher on Purpose
From Crypto 101 Media | Ad
It's a groundbreaking opportunity that could be poised for extraordinary gains.
The catalyst behind this surge is a massive new blockchain development…
YES, I WANT THE #1 CRYPTO NOW
A number of institutional investors have recently bought and sold shares of TELA. Paradigm Capital Management Inc. NY raised its stake in shares of TELA Bio by 143.8% in the 2nd quarter. Paradigm Capital Management Inc. NY now owns 1,256,200 shares of the company's stock valued at $5,904,000 after acquiring an additional 740,935 shares during the period. AIGH Capital Management LLC raised its stake in shares of TELA Bio by 17.1% in the 2nd quarter. AIGH Capital Management LLC now owns 1,656,655 shares of the company's stock valued at $7,786,000 after acquiring an additional 241,400 shares during the period. Nantahala Capital Management LLC grew its holdings in TELA Bio by 122.8% during the 2nd quarter. Nantahala Capital Management LLC now owns 2,445,667 shares of the company's stock worth $11,495,000 after acquiring an additional 1,347,801 shares in the last quarter. Vanguard Group Inc. grew its holdings in TELA Bio by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 1,006,052 shares of the company's stock worth $5,704,000 after acquiring an additional 7,199 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new position in TELA Bio during the 2nd quarter worth approximately $302,000. 94.35% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several research analysts recently issued reports on TELA shares. Lake Street Capital reduced their target price on shares of TELA Bio from $14.00 to $8.00 and set a "buy" rating for the company in a report on Tuesday, August 13th. Piper Sandler dropped their target price on shares of TELA Bio from $10.00 to $8.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 13th. Canaccord Genuity Group reiterated a "buy" rating and issued a $12.00 target price on shares of TELA Bio in a research report on Friday, October 4th. Finally, JMP Securities dropped their target price on shares of TELA Bio from $15.00 to $12.00 and set a "market outperform" rating on the stock in a research report on Tuesday, August 13th.
Check Out Our Latest Stock Report on TELA Bio
TELA Bio Company Profile
(
Get Free Report)
TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
